Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Do

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Endocrine-Related Cancer|August 3, 2022
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC studyJulien Hadoux, Thomas Walter, Christina Kanaan, et al.
The Journal of Clinical Endocrinology and Metabolism|October 14, 2015
Pregnancy in Women Previously Treated for an Adrenocortical CarcinomaPauline de Corbière, Katrin Ritzel, Laure Cazabat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2023
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid CancerSophie Leboulleux, Christine Do Cao, Slimane Zerdoud, et al.
The Journal of Clinical Endocrinology and Metabolism|August 28, 2013
Molecular screening for a personalized treatment approach in advanced adrenocortical cancerMaria Cristina De Martino, Abir Al Ghuzlan, Sebastien Aubert, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2021
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN networkJulien Hadoux, Christina Kanaan, Alice Durand, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 21, 2018
Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluationKarine Renaudin, Sarra Smati, Matthieu Wargny, et al.
The Journal of Clinical Endocrinology and Metabolism|July 26, 2013
One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paragangliomaSégolène Hescot, Sophie Leboulleux, Laurence Amar, et al.
Pediatric Blood & Cancer|May 23, 2024
Adolescent- and adult-onset neuroblastic tumor: A retrospective multicenter observational study of patients diagnosed in France between 2000 and 2020Orlane Magnier, Isabelle Schiff, Justine Cristante, et al.
Communications Medicine|July 6, 2026
OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancerChristoph Schultheiß, Brenda Besemer, Edith Willscher, et al.
Thyroid : Official Journal of the American Thyroid Association|October 19, 2023
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF NetworkArnaud Jannin, Fabiola Giudici, Christelle de la Fouchardière, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Endocrine-Related Cancer|August 3, 2022
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC studyJulien Hadoux, Thomas Walter, Christina Kanaan, et al.
The Journal of Clinical Endocrinology and Metabolism|October 14, 2015
Pregnancy in Women Previously Treated for an Adrenocortical CarcinomaPauline de Corbière, Katrin Ritzel, Laure Cazabat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2023
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid CancerSophie Leboulleux, Christine Do Cao, Slimane Zerdoud, et al.
The Journal of Clinical Endocrinology and Metabolism|August 28, 2013
Molecular screening for a personalized treatment approach in advanced adrenocortical cancerMaria Cristina De Martino, Abir Al Ghuzlan, Sebastien Aubert, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2021
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN networkJulien Hadoux, Christina Kanaan, Alice Durand, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 21, 2018
Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluationKarine Renaudin, Sarra Smati, Matthieu Wargny, et al.
The Journal of Clinical Endocrinology and Metabolism|July 26, 2013
One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paragangliomaSégolène Hescot, Sophie Leboulleux, Laurence Amar, et al.
Pediatric Blood & Cancer|May 23, 2024
Adolescent- and adult-onset neuroblastic tumor: A retrospective multicenter observational study of patients diagnosed in France between 2000 and 2020Orlane Magnier, Isabelle Schiff, Justine Cristante, et al.
Communications Medicine|July 6, 2026
OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancerChristoph Schultheiß, Brenda Besemer, Edith Willscher, et al.
Thyroid : Official Journal of the American Thyroid Association|October 19, 2023
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF NetworkArnaud Jannin, Fabiola Giudici, Christelle de la Fouchardière, et al.
Pageof 12